DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying,
and reduces appetite and food intake. Therapeutic approaches for enhancing ... Cited by 408 - Related articles - All 10 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among
193 outpatients with type 2 diabetes. The mean age was 56.6 years and the ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►endojournals.org F Fehse, M Trautmann, JJ Holst, AE Halseth … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Context: First-phase insulin secretion (within 10 min after a sudden rise in
plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin
mimetic exenatide has glucoregulatory activities in DM2, including glucose- ... Cited by 122 - Related articles - BL Direct - All 4 versions
MA Nauck, JJ Meier - Regulatory peptides, 2005 - Elsevier Glucagon-like peptide 1 (GLP-1) was discovered as an insulinotropic gut hormone,
suggesting a physiological role as an incretin hormone, ie, being responsible,
in part, for the higher insulin secretory response after oral as compared ... Cited by 107 - Related articles - All 6 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a
glucose-dependent manner, but its short half-life limits its therapeutic
potential. We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects ... Cited by 94 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org LL Baggio, Q Huang, TJ Brown, DJ Drucker - Diabetes, 2004 - Am Diabetes Assoc Peptide hormones exert unique actions via specific G protein–coupled
receptors; however, the therapeutic potential of regulatory peptides is
frequently compromised by rapid enzymatic inactivation and clearance from ... Cited by 94 - Related articles - BL Direct - All 11 versions
- ►tufts.edu [PDF] LL Baggio, DJ Drucker, 2006 - Annual Reviews Type 2 diabetes is characterized by hyperglycemia resulting from insulin
resistance in the setting of inadequate β-cell compensation. Currently
available therapeutic agents lower blood glucose through multiple ... Cited by 77 - Related articles - BL Direct - All 10 versions
- ►glucagon.com [PDF] - Free from Publisher MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate
control of postprandial hyperglycemia, weight gain, and, in the case of oral
agents, loss of efficacy over time. A better understanding of physiological ... Cited by 71 - Related articles - BL Direct - All 10 versions
JJ Meier, MA Nauck - Diabetes/Metabolism Reviews - interscience.wiley.com Post-translational proteolytic processing of the preproglucagon gene in the gut
results in the formation of glucagon-like peptide 1 (GLP-1). Owing to its
glucose-dependent insulinotropic effect, this hormone was postulated to ... Cited by 73 - Related articles - All 3 versions
